
India's Food Safety and Standards Authority (FSSAI) has banned the use of ashwagandha leaves and their extracts in health supplements, permitting only the roots for such products. This decision follows safety concerns raised by the Ministry of Ayush about potential health risks from leaf extracts, including liver toxicity and neurotoxic effects. The move affects the growing nutraceutical industry, where ashwagandha's market is projected to reach $928.5 million by 2026, with rising demand domestically and internationally. States have been directed to enforce compliance and take action against violations.
The articles primarily present official regulatory actions and government concerns without partisan framing. They include perspectives from the Ministry of Ayush and FSSAI, focusing on public health and industry impact. There is no evident political bias, as coverage centers on regulatory compliance and safety issues rather than political debate or controversy.
The tone across the articles is neutral and informative, emphasizing regulatory measures and safety considerations. While the ban may have economic implications for the nutraceutical sector, the coverage avoids emotive language, focusing instead on factual reporting of the decision and its rationale.
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| businessstandard | FSSAI bans use of ashwagandha leaves in supplements, flags safety concerns | Center | Neutral |
| mint | India bans wellness wonder ashwagandha's leaf products on health risk Today News | Center | Neutral |
mint broke this story on 18 Apr, 12:42 am. Other outlets followed.
Story is receiving appropriate media attention relative to public interest.
Institutions and figures named across source coverage.
Select a news story to see related coverage from other media outlets.